Physicians' Academy for Cardiovascular Education

GLP-1 receptor agonists: The cardiovascular benefits beyond glucose control

10' education - Aug. 27, 2018 - ESC 2018 - Munich, Germany - Filip K. Knop, MD, PhD - Copenhagen, Denmark - Online CME

Video navigation menu

  • Refresher of the incretin effect in healthy subjects 0:54
  • How to normalize the impaired incretin effect seen In T2DM patients? 6:27
  • GLP-1 has effects in multiple organs 8:37
  • How do the multiple effects of GLP-1 analogues translate into clinical endpoints? 13:41
  • How to use GLP-1RA in clinical practice? 14:41

Educational information

This lecture was part of a CME accredited symposium: "Outcomes of GLP-1 RA in Diabetes & CVD: What are the key opportunities for cardiology practice?", held during ESC 2018 in Munich, Germany.


Filip K. Knop, MD, PhD - endocrinologist, University of Copenhagen, Denmark


This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.


Funding for this educational program was provided by an unrestricted educational grant from Novo Nordisk

View slides of prof. Knop


This is available as accredited online CME for members. Click the button below to enroll:

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: